- Conditions
- Glioblastoma
- Interventions
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ad-RTS-hIL-12, Veledimex
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Morphea, Scleroderma, Localized, Scleroderma
- Interventions
- FCX-013, veledimex
- Genetic · Drug
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma
- Interventions
- Ad-RTS-hIL-12, veledimex
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
- Interventions
- Ad-RTS-hIL-12, veledimex
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
- Interventions
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Breast Cancer Nos Metastatic Recurrent
- Interventions
- Ad-RTS-hIL-12 and Veledimex, Palifosfamide
- Genetic · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Detroit, Michigan • Billings, Montana + 5 more
- Conditions
- Glioblastoma
- Interventions
- Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Jacksonville, Florida + 4 more